NovaBay Pharmaceuticals (NYSE:NBY) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report released on Tuesday. The brokerage issued a hold rating on the stock.

Separately, Ascendiant Capital Markets dropped their target price on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a research report on Monday, November 11th.

NovaBay Pharmaceuticals Price Performance

NovaBay Pharmaceuticals stock opened at $0.65 on Tuesday. The business has a 50 day simple moving average of $0.62 and a 200-day simple moving average of $0.70. NovaBay Pharmaceuticals has a 12 month low of $0.36 and a 12 month high of $9.08. The stock has a market capitalization of $3.19 million, a PE ratio of -0.01 and a beta of 0.65.

NovaBay Pharmaceuticals (NYSE:NBY) last released its earnings results on Thursday, November 7th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.32). The firm had revenue of $2.44 million during the quarter, compared to analyst estimates of $2.50 million. NovaBay Pharmaceuticals had a negative return on equity of 7,293.78% and a negative net margin of 102.72%. As a group, equities research analysts anticipate that NovaBay Pharmaceuticals will post -3.26 EPS for the current year.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.